First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature
- Authors: CHERNOVA NG1, ZVONKOV EE1, BADMAZHAPOVA DS1, SINITSYNA MN1, GREBENYUK LA1, SIDOROVA YV1, KOSTINA IE1, KOVRIGINA AM1, OBUKHOVA TN1, SUDARIKOV AB1, SAVCHENKO VG1
-
Affiliations:
- Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
- Issue: Vol 90, No 7 (2018)
- Pages: 77-81
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32789
- DOI: https://doi.org/10.26442/terarkh201890777-81
- ID: 32789
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N G CHERNOVA
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
Email: ngchernova@mail.ru
к.м.н., врач-гематолог отд-ния интенсивной химиотерапии лимфом, тел.: 8(495)612-48-10 (раб.), 8(916)660-27-63 (моб.); ; http://orcid.org/0000-0002-0827-4052 Moscow, Russia
E E ZVONKOV
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationд.м.н., зав. отд-нием; http://orcid.org/0000-0002-2639-7419 Moscow, Russia
D S BADMAZHAPOVA
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationаспирант; https://orcid.org/0000-0002-4223-2366 Moscow, Russia
M N SINITSYNA
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationн.с.; http://orcid.org/0000-0002-0750-8005 Moscow, Russia
L A GREBENYUK
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationведущий специалист по молекулярной биологии; http://orcid.org/0000-0003-2117-8775 Moscow, Russia
Y V SIDOROVA
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationк.м.н., с.н.с.; http://orcid.org/0000-0003-1936-0084 Moscow, Russia
I E KOSTINA
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationк.м.н., зав. отд-нием; https://orcid.org/0000-0003-4683-4118 Moscow, Russia
A M KOVRIGINA
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationд.б.н., зав. патологоанатомическим отд-нием; https://orcid.org/0000-0002-1082-8659 Moscow, Russia
T N OBUKHOVA
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationк.м.н., зав. лабораторией; https://orcid.org/0000-0003-1613-652X Moscow, Russia
A B SUDARIKOV
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationд.б.н., зав. лабораторией; https://orcid.org/0000-0001-9463-9187 Moscow, Russia
V G SAVCHENKO
Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federationакад. РАН, проф., генеральный директор; https://orcid.org/0000-0001-8188-5557 Moscow, Russia
References
- Swerdlow S.H, Campo E, Harris N.L, Jaffe E.S, Pileri S.A, Stein H, Thiele J, Arber D.A, Hasserjian R.P, Le Beau M.M, Orazi A, Siebert R. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC, 2017: 418-421.
- Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.International T-Cell Lymphoma Project. J Clin Oncol. 2008 (Sep 1); 26(25): 4124-30. https://doi: 10.1200/JCO.2008.16.4558
- Stein H, Foss H.D, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000 (Dec 1); 96(12):3681-95.
- Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001( Sep); 114(4):741-60.
- Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci P.G, Flenghi L, Martelli M.F, Santucci A. ALK+ lymphoma: clinico - pathological findings and outcome. Blood. 1999 (Apr 15); 93(8):2697-706.
- Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. Монография. М.: Издательство "Медицинское информационное агентство", 2007.
- Parrilla Castellar E.R, Jaffe E.S, Said J.W, Swerdlow S.H, Ketterling R.P, Knudson R.A, Sidhu J.S, Hsi E.D, Karikehalli S, Jiang L, Vasmatzis G, Gibson S.E, Ondrejka S, Nicolae A, Grogg K.L, Allmer C, Ristow K.M, Wilson W.H, Macon W.R, Law M.E, Cerhan J.R, Habermann T.M, Ansell S.M, Dogan A, Maurer M.J, Feldman A.L. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 (Aug 28); 124(9):1473-80. https://doi: 10.1182/blood-2014-04-571091
- Khoury J.D, Medeiros L.J, Rassidakis G.Z, Yared M.A, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin H.M, Lai R. Differential expression and clinical significance of tyrosine - phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1): 3692-3699.
- Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan W.C, Iqbal J, Piris M.A, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz L.D, Mevellec L, Vialard J.E., Piva R, Bertoni F, Rabadan R, Inghirami G. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27:516-532. https://doi: 10.1016/j.ccell.2015.03.006
- Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros L.J, Young K.H, Rassidakis G.Z. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large - cell lymphoma. Leukemia. 2017( Jul); 31(7):1633-1637. https://doi: 10.1038/leu. 2017.103
- Виноградова Ю.Е., Луценко И.Н., Капланская И.Б., Воробьев И.А., Самойлова Р.С., Горгидзе Л.А., Рыжикова Н.В., Валиев Т.Т., Гилязитдинова Е.А., Джулакян У.Л., Егорова Е.К., Звонков Е.Е., Красильникова Б.Б., Магомедова А.У., Марголин О.В., Марьин Д.С., Кременецкая А.М., Кравченко С.К., Воробьев А.И. Эффективность терапии различных вариантов анаплазированных Т-крупноклеточных лимфом. Терапевтический архив. 2008; 80(7): 33-37.
- Savage K.J, Harris N.L, Vose J.M, Ullrich F, Jaffe E.S, Connors J.M, Rimsza L, Pileri S.A, Chhanabhai M, Gascoyne R.D, Armitage J.O, Weisenburger D.D. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large - cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 (Jun 15); 111(12):5496-504. https://doi: 10.1182/blood-2008-01-134270
- Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho A.D, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 (Nov 4); 116(18): 3418-25. https://doi: 10.1182/blood-2010-02-270785
- d'Amore F, Relander T, Lauritzsen G.F, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod H.E. Up - front autologous stem - cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 (Sep 1); 30(25):3093-9. https://doi: 10.1200/JCO. 2011.40.2719
- Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn L.H, Villa D, Gascoyne R.D, Connors J.M, Savage K.J. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long - term survivors. Clin Oncol. 2013 (Jun 1); 31(16):1970-6. https://doi: 10.1200/JCO.2012.44.7524
- Vose J.M, Link B.K, Grossbard M.L, Czuczman M, Grillo-Lopez A, Fisher R.I. Long - term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 (Nov); 46(11):1569-73. https://doi: 10.1080/10428190500217312
- Younes A, Bartlett N.L, Leonard J.P, Kennedy D.A, Lynch C.M, Sievers E.L, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 (Nov 4); 363(19):1812-21. https://doi: 10.1056/NEJMoa1002965
- Pro B, Advani R, Brice P, Bartlett N.L, Rosenblatt J.D, Illidge T, Matous J, Ramchandren R, Fanale M, Connors J.M., Fenton K, Huebner D, Pinelli J.M, Kennedy D.A, Shustov A. Five - year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 (Dec 21); 130(25): 2709-2717. https://doi: 10.1182/blood-2017-05-780049
- Bartlett N.L, Chen R, Fanale M.A, Brice P, Gopal A, Smith S.E, Advani R, Matous J.V, Ramchandren R, Rosenblatt J.D, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 (Mar 19); 7:24. https://doi: 10.1186/1756-8722-7-24
- Abid M.B, Wang S, Loi H.Y, Poon L.M. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016 (Oct); 95(10):1725-6. https://doi: 10.1007/s00277-016-2746-3
- Al-Rohil R.N, Torres-Cabala C.A, Patel A, Tetzlaff M.T, Ivan D, Nagarajan P, Curry J.L, Miranda R.N, Duvic M, Prieto V.G, Aung P.P. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 (Dec); 43(12):1161-1166. https://doi: 10.1111/cup.12797
- Fanale M.A, Horwitz S.M, Forero-Torres A, Bartlett N.L, Advani R.H, Pro B, Chen R.W, Davies A, Illidge T, Huebner D, Kennedy D.A, Shustov A.R. Brentuximab vedotin in the front - line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 (Oct 1); 32(28): 3137-43. https://doi: 10.1200/JCO. 2013.54.2456
- A Comparison of Brentuximab Vedotin and CHP with Standard - of - care CHOP in the Treatment of Patients with CD30-positive Mature T-cell Lymphomas (ECHELON-2). ClinicalTrials.gov Identifier: NCT01777152.
- Программное лечение заболеваний системы крови: сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Издательство “Практика”, 2012.
- Горенкова Л.Г., Кравченко С.К. Результаты и перспективы лечения анапластической крупноклеточной лимфомы у взрослых пациентов. Гематология и трансфузиология. 2016; 61: 14.
![](/img/style/loading.gif)